aTyr Pharma, Inc. (LIFE) Announces Earnings Results, Beats Expectations By $0.07 EPS

aTyr Pharma, Inc. (NASDAQ:LIFE) posted its earnings results on Tuesday. The biotechnology company reported ($0.43) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.07, Bloomberg Earnings reports.

aTyr Pharma (NASDAQ LIFE) opened at $3.85 on Thursday. The company has a quick ratio of 6.13, a current ratio of 6.13 and a debt-to-equity ratio of 0.29. aTyr Pharma has a 12 month low of $2.10 and a 12 month high of $6.50.

A number of analysts recently weighed in on the stock. BMO Capital Markets set a $4.00 target price on shares of aTyr Pharma and gave the stock a “hold” rating in a report on Tuesday, August 15th. Zacks Investment Research lowered shares of aTyr Pharma from a “buy” rating to a “hold” rating and set a $3.25 target price on the stock. in a report on Wednesday, August 30th. Finally, ValuEngine lowered shares of aTyr Pharma from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $4.62.

TRADEMARK VIOLATION WARNING: “aTyr Pharma, Inc. (LIFE) Announces Earnings Results, Beats Expectations By $0.07 EPS” was published by Markets Daily and is owned by of Markets Daily. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.themarketsdaily.com/2017/11/16/atyr-pharma-inc-life-announces-earnings-results-beats-expectations-by-0-07-eps.html.

In related news, Director Paul Schimmel purchased 94,336 shares of the business’s stock in a transaction on Thursday, August 31st. The stock was acquired at an average price of $2.65 per share, with a total value of $249,990.40. Following the purchase, the director now directly owns 40,440 shares in the company, valued at $107,166. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO John Mendlein purchased 37,736 shares of the business’s stock in a transaction on Thursday, August 31st. The stock was bought at an average cost of $2.65 per share, with a total value of $100,000.40. The disclosure for this purchase can be found here. 33.30% of the stock is owned by insiders.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Earnings History for aTyr Pharma (NASDAQ:LIFE)

Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply